Citations

Clear

3942 citation(s) found for "To, Van".

Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study
Li, Katherine , Lin, Yi , Martin, Thomas G. , Han, Siyu, de, Rocío Montes , Suraneni, Mahipal, Hodkinson, Brendan P. , Wang, Feng, Kumar, Ashwini , Yin, Da , Smirnov, Denis A. , Patel, Jaymala , Lendvai, Nikoletta , Zhu, Jieqing, Koneru, Mythili, Patel, Nitin , Geng, Dong , Plaks, Vicki , Parekh, Samir , Donk, Niels W.C.J. van de , Han, Siyu, Gormley, Michael , Yuan, Jinzhou , Wang, Feng , Yin, Da, Madduri, Deepu , Harrison, Simon J

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 92-92

10.1182/blood-2025-92 Get It

Abstract Introduction: Cilta-cel is approved in the US and the EU for the treatment of patients (pts) with lenalidomide-refractory multiple myeloma (MM) after ≥1 prior line of therapy (pLOT), including a proteasome inhibitor and an immunomodulatory agent based on the CARTITUDE-1 (CART-1, NCT03548207) and CARTITUDE-4 (CART-4, NCT04181827) studies. Cilta-cel led to deep and durable responses and significant survival benefit in pts with relapsed/refractory MM (RRMM) after ≥3 pLOT in CART-1. In CART-4, cilta-cel led to a significant overall survival benefit with a higher proportion of pts achieving deep, sustained minimal residual disease negativity vs standard of care in pts with lenalidomide-refractory MM after 1–3 pLOT. We investigated the mechanism of action of cilta-cel by correlating biomarkers from peripheral blood and the bone marrow TME with progression-free survival (PFS) and number of pLOT in pts with RRMM from CART-1 and CART-4. Methods: Biomarker analyses were performed using peripheral blood and bone marrow aspirates (BMAs) collected in both CART-1 and CART-4 studies. Immunophenotyping by flow cytometry was performed using peripheral blood at baseline/time of apheresis in samples from both studies. Immune fitness at baseline was assessed in pts by pLOT and in association with PFS. Gene set enrichment scores were derived from RNA sequencing data of the TME using BMAs. Mixed-effects models were used to identify signatures/pathways modulated over time (day [D] 28 and at 6 months [mo] post infusion vs screening) and in association with PFS and pLOT. Results: In total, 176 CART-4 and 97 CART-1 pts received cilta-cel as study treatment. Immunophenotyping data were available from 248 peripheral blood samples (1 pLOT, n=56; 2 pLOT, n=61; ≥3 pLOT, n=131). At apheresis, CD4+ naïve T cells (%) were higher in pts with 1 or 2 pLOT, compared with those with ≥3 pLOT, while no difference was found in pts with ≥3 pLOT with further breakdown (i.e., 3–4 vs 5–6 vs ≥7 pLOT). Further, higher baseline levels of CD4+ naïve T cells were associated with longer PFS. These data suggest that the negative impact on peripheral immune fitness with the addition of LOT may plateau when pts have received ≥3 pLOT. TME gene expression data were available from 148 BMA samples (screening, n=50; D28, n=50; 6 mo, n=48) from CART-4. Analyses of gene expression signatures suggest depletion of B cells and antibodies at D28 post cilta-cel infusion, with partial recovery at 6 mo. This was corroborated in parallel by flow cytometry and immunoglobulin quantification. Further, elevated expression of genes associated with myeloid cells, including tumor-associated macrophages (TAM, likely M1), and of genes associated with cytotoxic T cells were also observed at D28. Elevated expression of genes associated with B-cell receptors, T-cell differentiation and activation, and cytokine signaling pathways were found at both D28 and 6 mo. Pts with longer PFS (>18 mo) had higher levels of M1 TAM at D28, while those with shorter PFS had higher levels of regulatory T cells and more suppressed interferon pathway genes at 6 mo, suggesting that relapse may be associated with a more suppressive immune response. In pts with fewer pLOT, more profound B-cell depletion on D28, better recovery at 6 mo, and elevated B-cell receptor signaling were inferred from gene expression data. Pts with 1 pLOT also demonstrated higher elevation of M1 TAM expression on D28 from screening as compared with pts with 3 pLOT, similar to what was observed in pts with longer PFS. Conclusions: Correlative biomarker data suggest that longer PFS is associated with better immune fitness at baseline and stronger immune responses post cilta-cel infusion, as observed in peripheral blood and within the TME of pts with RRMM in CART-1 and CART-4. The peripheral immune fitness was more pronounced in pts with 1 and 2 pLOT vs 3 pLOT and beyond, where deterioration plateaued. This suggests the impact of T-cell immune fitness on PFS may be limited beyond the third LOT. Importantly, other covariates, including factors within the immune TME and tumor burden, may play a significant role in balancing this compromised intrinsic T-cell immune fitness at apheresis, thereby contributing to PFS durability after 3 pLOT. Overall, these results support increased benefits in treating pts with MM with cilta-cel in earlier LOTs.
Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Rein, Lindsay , Boggs, Nathan A. , Yi, Cecilia Y. Arana , Elberink, Hanneke Oude , Radia, Deepti , Reiter, Andreas , Piris‐Villaespesa, Miguel , Dybedal, Ingunn , Panse, Jens , Vachhani, Pankit , Kirshenbaum, Arnold S. , Vaughn, Jennifer E. , Cerquozzi, Sonia , Fahrenholz, John M., Pomares, Helena , Üstün, Celalettin , Herrscher, Richard, Barète, Stéphane , Rivera, Candido E., Vadas, Peter , McCulloch, Derek, Keohane, Clodagh, Schafhausen, Philippe, Pilla, Amanda, Zhang, Jenna, Sun, Lei , Shah, Nisha , Jolin, Hina, Easton, Rachael, Sachs, Jessica, Bose, Prithviraj , Modena, Brian D. , Sabato, Vito , Hartmann, Karin , Akin, Cem , George, Tracy I. , Yi, Cecilia Arana , Oh, Stephen T. , Hunter, Anthony M. , Castells, Mariana , Livideanu, Cristina Bulai , Daele, Paul Van , Álvarez‐Twöse, Iván , Taparia, Minakshi , Mital, Andrzej , Hus, Marek , Romano, Alessandra , Lansigan, Frederick , Papayannidis, Cristina , Rondoni, Michela , Manning, Michael, Guilarte, Mar , Bernstein, Jonathan A. , Elena, Chiara , Orfali, Nina M. , Mannelli, Francesco , Shah, Nisha, Siebenhaar, Frank , DeAngelo, Daniel J.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 80-80

10.1182/blood-2025-80 Get It

Abstract Background: Systemic mastocytosis (SM) comprises a spectrum of subtypes characterized by neoplastic mast cell (MC) infiltration of tissues and release of MC mediators. Non-advanced SM (NonAdvSM), including indolent SM (ISM), smoldering SM (SSM), and bone marrow mastocytosis (BMM) subtypes, is the most prevalent form of SM. NonAdvSM can be associated with debilitating symptomology which can significantly impair quality of life. The gain-of-function somatic KIT c.2447 C>T (p.D816V) mutation is found in up to 95% of patients with SM. Bezuclastinib (CGT9486) is an oral, potent, and selective type 1 tyrosine kinase inhibitor with activity against KIT D816V. Results from Summit (NCT05186753) Part 1 informed the recommended phase 2 dose (100 mg QD bezuclastinib) for Part 2. We report topline results from the 24-week assessment of Summit Part 2. Methods: Summit is a multi-center, randomized, double-blind, placebo (PBO)-controlled Phase 2 trial of bezuclastinib in patients with NonAdvSM who had inadequate symptom control despite best supportive care (BSC) medications. The primary endpoint was 24-week mean change from baseline in Mastocytosis Symptom Severity Daily Diary (MS2D2) total symptom score (TSS) (range 0–110), which is a fit-for-purpose patient-reported outcome measure of NonAdvSM symptom severity. Key secondary endpoints included the proportion of patients with ≥50% reduction in serum tryptase, KIT p.D816V variant allele frequency (VAF), bone marrow (BM) MC burden, and MS2D2 TSS, ≥30% TSS reduction. Patients were randomized 2:1 to receive 100mg QD bezuclastinib + BSC or PBO + BSC. Results: As of May 22, 2025, 179 patients were enrolled in Part 2: 119 were randomized to receive bezuclastinib and 60 to placebo. Patients enrolled were representative of the NonAdvSM population with moderate to severe symptoms. Median age (range) was 51 (23-78) years; 65.9% female; mean (SD) baseline MS2D2 TSS 55.6 (19.8); 82% of patients had ISM, 11% had BMM, and 7% had smoldering SSM. At baseline, median (range) KIT p.D816V VAF in whole blood, BM MC burden, and serum tryptase was 0.25% (0-34%), 10% (1-75%), and 40 (6-692) ng/mL, respectively. Bezuclastinib demonstrated statistically significant superiority to placebo on all primary and key secondary endpoints. At Week 24, bezuclastinib led to significantly greater symptom improvement vs placebo (LS mean [95% CI] MS2D2 TSS change: –24.3 [–27.6 to –21.1] vs –15.4 [–19.6 to –11.2]; placebo-adjusted difference: –8.9 points; P=0.0002). A ≥50% reduction in serum tryptase was achieved in 87.4% of bezuclastinib-treated patients vs 0% on placebo (P<0.0001). Significantly more patients receiving bezuclastinib achieved ≥50% reductions in KIT D816V VAF, serum tryptase, BM MCs (P<0.0001), MS2D2 TSS (P=0.01), and ≥30% reduction in MS2D2 TSS (P=0.0004). Most treatment-emergent adverse events (TEAEs) were low grade (gr; 70% Gr 1) and reversible. The most common TEAEs (≥10%) in any treatment group and occurring in greater frequency in the bezuclastinib arm were hair color changes (69.5% vs 5.0%), altered taste (23.7% vs 0%), nausea (22.0% vs 13.3%), increased ALT/AST (22.0% vs 6.6%), headache (17.8% vs 11.7%), alopecia (11.9% vs 3.3%), and increased ALP (10.2% vs 3.3%). TEAEs (≥10%) that occurred more often in the placebo group were diarrhea (13% vs 18%), dizziness (10% vs 12%), fatigue (7% vs 12%), and arthralgia (6% vs 15%). ALT/AST elevations ≥Gr 3 were experienced by 5.9% of patients. The only hepatic adverse events (AEs) reported were transient lab abnormalities; none required hospitalization. Treatment-related AEs requiring dose reductions occurred in 11% of patients receiving bezuclastinib. All discontinuations (5.9%) due to treatment-related AEs were due to transaminase elevations; all fully resolved. Conclusions: At 24-weeks, bezuclastinib 100 mg QD demonstrated statistically and clinically significant improvements in symptom burden and biomarkers of disease vs placebo in patients with NonAdvSM. The treatment was generally well-tolerated and effective across a population that is representative of the real-world NonAdvSM population, including SSM. These results support the use of bezuclastinib to reduce SM burden and symptoms in pts with NonAdvSM, and a potentially disease-modifying impact.
A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Shah, Urvi A. , Cogrossi, Laura Lucia , Garcés, Juan‐José , Policastro, Anna , Castro, Francesca , Derkach, Andriy , Fei, Teng , DeWolf, Susan , Grioni, Matteo , Sisti, Sofia , Blaslov, Jenna , Adintori, Peter , McAvoy, Devin , Baichoo, Mirae , Paredes, Jenny , Anuraj, Aishwarya , Pohl, Charlotte , Zinsmeyer, Victoria , Gipson, Brianna , Marchigiani, Camilla , Pagani, Sara , Salehi, Erica , Block, Torin , Korde, Neha , Tan, Carlyn , Hultcrantz, Malin , Hassoun, Hani , Scordo, Michael , Lahoud, Oscar , Landau, Heather , Peled, Jonathan U. , Chesi, Marta , Mailankody, Sham , D’Souza, Anita , Iyengar, Neil M. , Adintori, Peter A , Hosszu, Kinga K , McAvoy, Devin , Baichoo, Mirae , Cross, Justin R , Paredes, Jenny , Anuraj, Aishwarya , Raj, Sandeep S , Pohl, Charlotte , Zordan, Paola , Zinsmeyer, Victoria , Jesus Faustino Ramos, Ruben J , Lorenzoni, Marco , Gipson, Brianna , Maclachlan, Kylee , Gradissimo, Ana , Boiocchi, Leonardo , Aleynick, Nathan , Marchigiani, Camilla , Pagani, Sara , Salehi, Erica , Koche, Richard P , Chaligne, Ronan , Block, Torin , Korde, Neha , Tan, Carlyn R , Hultcrantz, Malin , Hassoun, Hani , Shah, Gunjan L , Scordo, Michael , Lahoud, Oscar B , Chung, David J , Landau, Heather , Peled, Jonathan U , Clementi, Nicola , Chesi, Marta , Bergsagel, P. Leif , Mailankody, Sham , Pollak, Michael N , D'Souza, Anita , Landgren, C Ola , Chimonas, Susan , Giralt, Sergio , Usmani, Saad , Iyengar, Neil M , Lesokhin, Alexander M , van den Brink, Marcel R M , Bellone, Matteo , Shah, Urvi A , Derkach, Andriy , Garces, Juan-Jose , Fei, Teng , Maclachlan, Kylee , Aleynick, Nathan , Shah, Gunjan L. , Bergsagel, P. Leif , Pollak, Michaël , Landgren, Ola , Giralt, Sergio , Usmani, Saad Z. , Lesokhin, Alexander M. , Bellone, Matteo

Mayo Clinic

Cancer Discovery | December 4, 2025 | Volume: 16 | Issue: 4 | Pages: 697-720

10.1158/2159-8290.cd-25-1101 | PMID 41342739 Get It

Abstract Consumption of a Western diet and high body mass index (BMI) are risk factors for progression from premalignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber, plant-based diet (HFPBD; meals for 12 weeks, coaching for 24 weeks) to 23 participants with myeloma precursor states and elevated BMI. The intervention was feasible and improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease progression trajectory improved (n = 2) or was stable. Findings were translated to Vk*MYC mice modeling the myeloma precursor state, in which a high-fiber diet (HFD) delayed disease progression through improved metabolism and microbiome composition, leading to increased short-chain fatty acid production that reinvigorated antitumor immunity and inhibited tumor growth. These effects from fiber consumption were independent of calorie restriction and weight loss. A HFD is a low-risk intervention that may delay progression to myeloma. Significance: A HFPBD in participants with precursor plasma cell disorders and an elevated BMI improved metabolic, microbiome, and immune biomarkers of disease. In a subset, it may delay progression to myeloma. In mouse models, a HFD delayed progression to myeloma independent of calorie restriction. See related commentary by Fairfield and Reagan, p. 623
Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa
Garg, Amit , Strunk, Andrew , Midgette, Bria, Frasier, Kelly , Cohn, Erica, Aarts, Pim , Alhusayen, Raed , Bechara, Bitte Falk G., Brassard, Alain, Brown, Debra, Emtestam, Lennart , Benhadou, Farida , Fernández‐Peñas, Pablo , Gebauer, Kurt , Horváth, Barbara , Marzano, Angelo Valerio , Orenstein, Lauren A.V. , Pascual, J.C. , Piguet, Vincent, Resnik, Barry I., Roth, Gretchen M. , Straalen, Kelsey van, Ingram, John R , Ingram, J R , Garg, Amit, Cohn, Erica, Alavi, Afsáneh , Bettoli, Vincenzo , Chandran, Nisha Suyien , Choon, Siew Eng , Cohen, Steven R. , Daveluy, Steven , Mármol, V. del , Dellavalle, Robert Paul , Flowers, Richard Hal , Frew, John W. , Giamarellos‐Bourboulis, Evangelos J. , Goldfarb, Noah , Hsiao, Jennifer L. , Jemec, Gregor B. E. , Lowes, Michelle A , Matusiak, Łukasz , Micheletti, Robert , Oon, Hazel H. , Ortega‐Loayza, Alex G. , Paek, So Yeon , Rosmarin, David M. , Sayed, Christopher J. , Silva, Dimitri Luz Felipe da , Thorlacius, Linnea , Tzellos, Thrasyvoulos , Zee, Hessel H. van der , Straalen, Kelsey R. van , Ingram, John R.

Mayo Clinic

JAMA Dermatology | November 26, 2025 | Volume: 162 | Issue: 1 | Pages: 72

10.1001/jamadermatol.2025.4652 | PMID 41296358 Get It

Importance Accurate classification and reliability in assessment for lesions of hidradenitis suppurativa (HS) by investigators is critical to the determination of responder status and to overall data quality in clinical trials. Objective To establish consensus-based morphological definitions of HS lesions and guidance statements that standardize investigator lesion assessments for implementation in clinical trials. Evidence Review Health professionals (primarily dermatologists) with expertise in the measurement of HS disease activity as well as novice raters completed a preliminary questionnaire in which participants were asked to assess images of HS lesions and provide qualitative feedback on their decision making. Based on this feedback, detailed morphologic definitions for lesions and guidance statements that standardize lesion assessments were formulated and presented for consensus voting in 2 electronic Delphi surveys. A virtual group discussion after round 1 supported participants in round 2 voting. Findings Response rates were 84.7% (50 of 59), 86.0% (43 of 50), and 90.9% (40 of 44) in the preliminary, electronic Delphi round 1, and electronic Delphi round 2 surveys, respectively. Morphological definitions for 11 lesion types achieved the prespecified 70% consensus threshold, with 9 definitions reaching at least 90% agreement. After 2 electronic Delphi rounds, 16 of 18 guidance statements achieved the prespecified consensus threshold, with 13 statements receiving endorsement from more than 80% of participants. Two guidance statements related to assessment of tunneled plaques with multiple openings and assessment of scalp lesions failed to reach consensus. Conclusions and Relevance Common morphologic definitions and guidance that standardize assessment of HS lesions can be implemented in clinical trial protocols and investigator trainings with the goals of improving accuracy and reliability of investigator ratings.
Mitigating off target B cell transduction during in situ CAR T cell induction 3591
Hinson, Destin T , Keulen, Virginia P. Van , Hansen, Michael J. , Peña, Alvaro, Jenkins, James W. , Johnson, Aaron J. , Pease, Larry R. , Johnson, Aaron J. , Barry, Michael A.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1373 Get It

Abstract Description Therapeutic in situ chimeric antigen receptor (isCAR) T cells can be generated by targeting activated T cells within a lymph node (LN) with retroviruses encoding CARs. While isCAR T cells are successfully generated by intradermal LN priming using adenovirus encoding allogeneic MHC in all mouse lines tested, differences in emerging therapeutic peripheral isCAR T cells are found in a strain dependent manner. Potentially harmful off target retroviral transduction of B cells with CARs is observed within the targeted LN. Here we report the blockade of B cell transduction using anti-CD20 antibody B cell depletion with the introduction of anti-CD19 chimeric antigen receptors into the activated CD8+ T cells. Lymphocytes were analyzed in blood and LN following isCAR T cell generation. When B cells were depleted by systemic administration of anti-CD20 antibodies during isCAR T cell induction, >97.5% systemic depletion of B cells was achieved. Whereas very small numbers of CAR transduced B cells were found in the blood of mice not treated with anti-CD20, none were observed in animals systemically depleted of B cells. In contrast, CAR B cells persisted in the LN of local anti-CD20 treated animals. However, animals expressing dominant CD8+ isCAR T cell populations eliminated LN B cells expressing CARs by week two. Furthermore, systemic treatment of lymphoma in animals with anti-CD20 antibody complemented anti-CD19 isCAR T therapy while blocking off target B cell transduction. Funding Sources Mayo Clinic Ventures Mayo Clinic Graduate School of Biomedical Sciences Mayo Clinic Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
MHC Class II defines cellular mechanisms mediating spontaneous rejection and the tumor microenvironment of breast carcinomas expressing modeled tumor neoantigens 2806
Jenkins, James W. , Peña, Alvaro, Castro, Sarah A, Keulen, Virginia P. Van , Foster, Sean, Rios-Cruz, Pablo E, Yakubov, Joshua, Hinson, Destin T , Olivier, S., Felts, Sara J. , Johnson, Aaron J. , Pease, Larry R. , Hansen, Michael J., Olivier, Samuel, Pavelko, Kevin D. , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.687 Get It

Abstract Description This study dissects mechanisms of spontaneous tumor rejection leading to better understanding of successful immune responses to cancer. Cancers persist despite expression of tumor-specific neoantigens promoting ongoing anti-tumor immune responses. While some occult tumor cells likely are cleared by effective anti-tumor immune responses, the targeted antigens are not easily identifiable as those cells spontaneously disappear. Congenic mouse breast carcinoma models expressing a defined protein mimicking neoantigens were used to dissect the protective spontaneous immune response. BALB/c (MHC H-2d) mice challenged with BALB/c breast tumors expressing the rat-erbB2 oncoprotein succumb to their tumors despite demonstrated tumor immunogenicity, mimicking known patient responses to cancer. Meanwhile, H-2b positive BALB.B and H-2d/H-2b F1 hybrid mice spontaneously eliminate genetically matched tumors in an MHC-II dependent manner. CD4+ T-cells and B-cells or the rat-erbB2-specific antibodies they produce are crucial mediators of this protective response. Differences in the tumor microenvironments in rat-erbB2+ tumor-bearing BALB.B and BALB/c mice at the time of fate decision in the models reflect the differences between effective and ineffective anti-tumor immunity. Identifying the nature of the optimal MHC-II antigens, how they activate protective CD4+ T-cells, and the interactions that promote protective antibodies will better inform future cancer therapies. Funding Sources Bernie Fineman Research Fund Mayo Clinic Center for Biomedical Discovery Mayo Clinic Department of Immunology Mayo Clinic Graduate School of Biomedical Sciences NIH Traning Grant 5 R25 GM 55252 Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Therapeutic in situ CAR T cells in genetically humanized HLA DQ8 mouse models 4607
Pease, Larry R. , Hansen, Michael, Keulen, Virginia P. Van , Peña, Alvaro, Parks, Christopher R., Guttormson, Matthew R., Jenkins, James W. , Hinson, Destin T , Powell, Noah J., Felts, Sara J. , Johnson, Aaron R. , Parks, Christopher R., Guttormson, Matthew C. , Powell, Noah J., Taneja, Veena , Mangalam, Ashutosh K. , Barry, Michael A.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.2267 Get It

Abstract Description Antigen receptor (CAR) T cells can be generated in vivo within the natural lymph node (LN) environment as the immune response to a virus infection unfolds. This in situ approach entails priming LNs with intradermal inoculations of replication defective adenoviruses encoding MHC class I and class II allo/xeno-antigens. Universal transplant antigens were devised for LN priming by introducing tryptophan into amino acid position 162 of the MHC HLA-A2:01 class I heavy chain and by using the mouse MHC class II beta chain to form chimeric class II antigens with endogenous class II alleles. The virus encoded mismatched MHC antigen presenting molecules are expressed functionally in the LN following intradermal inoculation provoking polyclonal T cells responses. Three days later CAR T cells are generated by directly injecting retroviruses encoding CARs of interest into the responding LN. Mouse CD19-specifc CAR T cells created in this manner in B6-DQ8 and DQ8/A2 mice effectively target endogenous B cells and are therapeutic in male and female Emu-myc lymphomas demonstrating the potential for the generating functional CAR T cells directly in vivo. While in situ CAR T cells are readily produced in B6, B6-IA0/DQ8, B6-IA0/DQ8/A2, and B6-IA0/DQ6 LNs, functional differences among the strains emerged in the periphery suggesting that properties of the autoimmune-associated HLA DQ8 class II allele is particularly reactive during the production of CAR T cells in vivo. Funding Sources MustangBio, Inc Mayo Clinic Center of Biomedical Research Mayo Clinic Department of Immunology Mayo Clinic Graduate School of Biomedical Science Fraternal Order of Eagles Mayo Clinic Ventures NIH R21 AI 097337 NIH R01 CA 178804 NIH T32 AI 07425 Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Thalamic Stimulation Induced Changes in Network Connectivity and Excitability in Epilepsy
Gregg, Nicholas M. , Valencia, Gabriela Ojeda , Pridalova, Tereza, Huang, Harvey , Křemen, Václav , Lundstrom, Brian N. , Gompel, Jamie J. Van , Miller, Kai J. , Worrell, Gregory A. , Hermes, Dora , Ojeda Valencia, Gabriela , Van Gompel, Jamie J , Kremen, Vaclav , Worrell, Gregory A , Lundstrom, Brian Nils , Gregg, Nicholas M , Hermes, Dora , Huang, Harvey

Mayo Clinic

Annals of Neurology | November 20, 2025 | Volume: 99 | Issue: 3 | Pages: 748-760

10.1002/ana.78087 | PMID 41263571 Get It

Objective The effects of deep brain stimulation (DBS) manifest across multiple timescales, spanning seconds to months, and involve direct electrical effects, neuroplasticity, and network reorganization. In epilepsy, the delayed impact of DBS on seizures presents challenges for optimization. Single‐pulse stimulation and resulting brain stimulation evoked potentials (BSEPs) provide a means to assess effective connectivity and network excitability. This study integrates BSEPs and short trials of DBS during stereoelectroencephalography (sEEG) to map seizure network engagement, modulate network dynamics, and monitor excitability and interictal abnormalities for biomarker informed neuromodulation. Methods Ten individuals with drug resistant epilepsy undergoing clinical sEEG were enrolled in this retrospective cohort study of epilepsy neuromodulation biomarkers. Each patient underwent a trial of high frequency (145Hz) thalamic DBS. BSEPs were acquired before and after DBS trials. Baseline BSEP amplitude assessed seizure network engagement, and modulation of amplitude (pre vs post DBS) assessed change in network excitability. Interictal epileptiform discharges were tracked by an automated classifier. Results Baseline BSEPs delineated distinct patterns of network engagement between thalamic subfields with maximal frontotemporal engagement achieved with stimulation of the anterior nucleus of the thalamus‐ventral anterior nucleus junction. DBS delivered for >1.5 hours reduced BSEP amplitudes compared to baseline, and the degree of modulation correlated with baseline connectivity strength. Shorter DBS trials did not induce reliable BSEP amplitude suppression, but did immediately suppress interictal epileptiform discharge rates in well‐connected seizure networks. Interpretation BSEPs and trials of DBS during sEEG provide novel network biomarkers to evaluate the modulation of large‐scale networks across multiple timescales, advancing biomarker informed neuromodulation. ANN NEUROL 2026;99:748–760
Neurodevelopmental effects of genetic frontotemporal dementia mutations revealed by total intracranial volume differences
So, Isis , Bouzigues, Arabella , Russell, Lucy L. , Foster, Phoebe H. , Ferry‐Bolder, Eve , Swieten, John C. van, Jiskoot, Lize C, Laforce, Robert, Graff, Caroline , Galimberti, Daniela , Vandenberghe, Rik, Xiong, Chengjie , Sorbi, Sandro, Pasquier, Florence, Ducharme, Simon , Butler, Christopher , Ber, Isabelle Le, Masellis, Mario, Moreno, Fermín , Borroni, Barbara , Kolander, Tyler, Mester, Carly , Brushaber, Danielle , Kantarci, Kejal , Heuer, Hilary W. , Forsberg, Leah K. , Boxer, Adam L. , Rosen, Howard J., Investigators, on behalf of Frontotemporal Dementia Prevention Initiative (FPI), Bocchetta, Martina , Jiskoot, Lize C. , Galimberti, Daniela , de Mendonça, Alexandre , Tartaglia, Maria Carmela , Rowe, James B , Synofzik, Matthis , Mester, Carly , Finger, Elizabeth C. , Kantarci, Kejal , Xiong, Chengjie , Russell, Lucy L , Bocchetta, Martina , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Borroni, Barbara , Swieten, John C. van , Seelaar, Harro , Sánchez‐Valle, Raquel , Laforce, Robert , Vandenberghe, Rik , Mendonça, Alexandre de , Tiraboschi, Pietro , Santana, Isabel , Gerhard, Alexander , Sorbi, Sandro , Otto, Markus , Pasquier, Florence , Ber, Isabelle Le , Rowe, James B. , Synofzik, Matthis , Rohrer, Jonathan D. , Boeve, Bradley F. , Investigators, on behalf of Frontotemporal Dementia Prevention Initiative (FPI)

Mayo Clinic

Journal of Alzheimer’s Disease | November 19, 2025 | Volume: 109 | Issue: 1 | Pages: 278-290

10.1177/13872877251393414 | PMID 41259271 Get It

Background Converging evidence hints at neurodevelopmental effects in people at risk of genetic frontotemporal dementia (FTD). Objective We investigated total intracranial volume (TIV), a neuroimaging marker of neurodevelopment, and years of education differences between adult mutation carriers and familial non-mutation carriers, as measures of the structural and functional neurodevelopmental effects of FTD-causing genetic mutations. Methods This cross-sectional cohort study, facilitated through the FTD Prevention Initiative (FPI), included 902 adult pathogenic mutation carriers of GRN , MAPT , or C9orf72 , and 532 familial non-carriers. ANCOVAs were computed to compare TIV and education between groups per gene. Pearson's correlations were used to examine associations between TIV and education. Results Mutation carriers (mean ± SD age = 50.0 ± 13.2 years, sex = 55% female, n ( GRN ) = 298, n( MAPT ) = 187, n ( C9orf72 ) = 417) were compared to familial non-carriers (age = 48.0 ± 12.9 years, sex = 58% female, n ( GRN ) = 201, n( MAPT ) = 114), n ( C9orf72 ) = 217). Consistent with prior findings in young adults, GRN carriers showed larger TIV, on average by 20531 mm 3 , compared to familial non-carriers (95% CI [85.4, 40977], p = 0.049, η 2 p = 0.008). Larger TIV correlated with higher years of education in GRN carriers (95% CI [0.01, 0.24], r (295) = 0.12, p = 0.03) and GRN non-carriers (95% CI [0.08, 0.34], r(198) = 0.21, p = 0.002). MAPT carriers demonstrated smaller TIV than non-carriers, on average by 29896 mm 3 (95% CI [–58248, −1545], p = 0.039, η 2 p = 0.02). Models with C9orf72 and education as outcome variables did not reveal significant differences. Conclusions In support of the neurodevelopmental hypothesis of FTD, GRN and MAPT mutations are linked to structural neurodevelopmental changes in TIV. Further research is needed to identify mechanisms underlying neurodevelopmental influences of FTD mutations and ascertain their suitability as intervention targets.
Isolation and genomic analysis of seven phages active against carbapenem-resistant Klebsiella pneumoniae
Cuello, Luz , Parmar, Krupa , Supandy, Adeline , Tyne, Daria Van , Patel, Robin , Van Tyne, Daria , Patel, Robin

Mayo Clinic

Microbiology Resource Announcements | November 18, 2025 | Volume: 14 | Issue: 12 | Pages: No page available

10.1128/mra.00768-25 | PMID 41251356 Get It

ABSTRACT The genomic sequences of seven phages isolated from municipal sewage in Rochester, Minnesota, USA, using Klebsiella pneumoniae strains ( bla KPC carriers) as hosts are reported. These phages are lytic and belong to the Ackermannviridae, Drexlerviridae , and Zobellviridae families. No known antimicrobial resistance or virulence genes were found within their genomes.